MHB3® is a patent pending, modified hyaluronan biopolymer with superior oral absorption and bioavailability characteristics. It is marketed as a dietary supplement ingredient for Systemic Joint Health Enhancement with supportive fundamental scientific and clinical research. MHB3® is molecularly engineered using a proprietary process that assures consistency in molecular profile, molecular weight, and polydispersity. Extra-cellular microbial production assures that MHB3® is pure, consistent and vegan. Microbial production eliminates concerns about extraneous proteins from animal-derived raw materials. MHB3® is not genetically modified and does not contain any genetically modified ingredients.
Researchers at the London Health Sciences Center have shown that oral administration of MHB3® formulations promotes a size distribution of hyaluronan in the plasma that is ideal for efficient joint function. Specifically, the proportion of hyaluronan that is high molecular weight - pro-joint function - is increased, and the proportion of hyaluronan that is low molecular weight- detrimental to joint function - is decreased. The fundamental mechanism underlying these findings remains to be elucidated, but the results are consistent with other studies showing hyaluronan of the molecular weight range was altered to enhance joint function when delivered orally.
The critical difference between MHB3® hyaluronan and other joint products is the controlled pre-clinical and clinical testing that confirms its bioavailability (the ease with which it reaches the system), safety and effectiveness.